AstraZeneca PLC (AZN)vsDaxor Corporation (DXR)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
DXR
Daxor Corporation
$11.47
+5.17%
HEALTHCARE · Cap: $58.84M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 229921226% more annual revenue ($61.37B vs $26,690). DXR leads profitability with a 34359.0% profit margin vs 17.0%. DXR trades at a lower P/E of 6.2x. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
DXR
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for DXR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 34359 of every $100 in revenue as profit
Earnings expanding 329.3% YoY
Every $100 of equity generates 23 in profit
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Revenue declined 82.6%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : DXR
The strongest argument for DXR centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 34359.0% and operating margin at -9661.0%.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : DXR
The primary concerns for DXR are Market Cap, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while DXR is a declining play — different risk/reward profiles.
DXR carries more volatility with a beta of 0.27 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 45/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Daxor Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Daxor Corporation, a medical device company, provides cryobank and biotechnology services in the United States. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?